A Pilot, Open-Label Study of Adjunctive Therapy With Lovaza in Hypertriglyceridemic, HIV-Infected Subjects Who Switched Protease Inhibitor to Once-Daily Lexiva 1400mg Plus Norvir 100mg Plus Optimized Background.

Trial Profile

A Pilot, Open-Label Study of Adjunctive Therapy With Lovaza in Hypertriglyceridemic, HIV-Infected Subjects Who Switched Protease Inhibitor to Once-Daily Lexiva 1400mg Plus Norvir 100mg Plus Optimized Background.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2012

At a glance

  • Drugs Fosamprenavir; Omega-3-acid ethyl esters; Ritonavir
  • Indications HIV-1 infections; Hypertriglyceridaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BuLLET
  • Most Recent Events

    • 17 Apr 2012 Actual patient number (36) added as reported by ClinicalTrials.gov.
    • 17 Apr 2012 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 17 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top